Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Vaccine entities : Merck & company, inc. save search
Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
Published: 2024-03-19 (Crawled : 13:30) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.0%
H: 0.68%
C: 0.63%
pneumococcal vaccine merck positive
Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9
Published: 2024-03-13 (Crawled : 11:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.41%
H: 0.04%
C: -0.81%
gardasil vaccine merck trials
Anixa Biosciences Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial
Published: 2023-08-07 (Crawled : 14:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.28%
H: 0.94%
C: 0.76%
ANIX | $3.12 0.65% 0.64% 33K
|
Health Technology
|
| O: 0.0%
H: 2.66%
C: -4.27%
keytruda arm vaccine breast cancer ongoing trial
Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
Published: 2023-07-27 (Crawled : 14:20) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.09%
H: 0.35%
C: -1.84%
pneumococcal vaccine merck trials
Merck and Moderna Announce Exercise of Option by Merck for Joint Development and Commercialization of Investigational Personalized Cancer Vaccine
Published: 2022-10-12 (Crawled : 12:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.22%
H: 0.52%
C: -0.91%
MRNA S | $101.44 -0.55% -0.55% 2.6M
|
Health Technology
|
| O: 12.29%
H: 4.36%
C: -3.57%
vaccine commercialization cancer
Merck Recognized on Fortune’s 2022 Change the World List for Expanding Access to HPV Vaccines
Published: 2022-10-10 (Crawled : 14:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 2.66%
H: 1.84%
C: 0.61%
change hpv vaccine
Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Infants and Children
Published: 2022-09-16 (Crawled : 12:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.17%
H: 1.47%
C: 1.29%
chmp children positive vaccine pneumococcal
Merck Presents Positive Results from Phase 1/2 Study Evaluating V116, the Company’s Investigational Pneumococcal Conjugate Vaccine for Adults
Published: 2022-06-21 (Crawled : 11:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.65%
H: 0.0%
C: 0.0%
vaccine positive phase 1 pneumococcal
Expansion of Elkton, Virginia Manufacturing Facility to Further Increase Merck’s HPV Vaccine Supply and Support Broader and Equitable Access
Published: 2022-04-04 (Crawled : 12:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.02%
H: 0.47%
C: -0.01%
expansion vaccine hpv
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children
Published: 2021-12-01 (Crawled : 12:30) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.98%
H: 1.83%
C: -1.44%
fda application license children vaccine fda acceptance pneumococcal
Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Individuals 18 Years of Age and Older
Published: 2021-10-15 (Crawled : 14:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.17%
H: 1.1%
C: 0.17%
positive chmp vaccine order pneumococcal
Merck Announces VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Met Key Immunogenicity and Safety Endpoints in Phase 3 Pivotal Trial Evaluating Use in Infants, PNEU-PED (V114-029)
Published: 2021-08-25 (Crawled : 12:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: -0.95%
vaccine phase 3 trial pneumococcal
New COVID-19 Vaccination Mandates Make Rapid COVID Tests More Essential Than Ever
Published: 2021-08-19 (Crawled : 13:00) - prnewswire.com
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.1%
H: 1.84%
C: 0.97%
MRNA S | $101.44 -0.55% -0.55% 2.6M
|
Health Technology
|
| O: -3.46%
H: 2.58%
C: -2.46%
CODX | $1.16 4.2% 18K
|
Health Technology
|
| O: -1.2%
H: 3.75%
C: 0.91%
COCP | $1.495 -1.39% 7.6K
|
Health Technology
|
| O: 0.0%
H: 0.97%
C: 0.0%
covid covid test test vaccine covid-19
Merck and Sanofi’s First and Only Six-in-One Pediatric Combination Vaccine Now Available in the United States
Published: 2021-06-01 (Crawled : 12:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.22%
H: 0.11%
C: -1.16%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.93%
H: 0.09%
C: -0.87%
vaccine
Sanofi and Merck's first and only six-in-one pediatric combination vaccine now available in the United States
Published: 2021-06-01 (Crawled : 11:00) - prnewswire.com
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.22%
H: 0.11%
C: -1.16%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.93%
H: 0.09%
C: -0.87%
vaccine
Merck Announces Positive Topline Results from PNEU-DIRECTION (V114-027) and PNEU-PLAN (V114-024) Phase 3 Pediatric Studies for V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine
Published: 2021-05-20 (Crawled : 11:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -4.02%
H: 1.34%
C: 0.92%
positive results topline vaccine phase 3 pneumococcal
Gabrielle Union-Wade Joins 'Don't Skip' Campaign to Encourage Doctor Well-Visits and Recommended Vaccinations
Published: 2021-05-17 (Crawled : 12:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.49%
H: 1.91%
C: 1.53%
vaccine
Thanks to Accelerated COVID-19 Research, New Therapeutic Vaccines May Soon Be Upon Us
Published: 2021-03-25 (Crawled : 13:15) - prnewswire.com
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.24%
H: 0.25%
C: -0.46%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.44%
H: 1.64%
C: 1.13%
MRNA S | $101.44 -0.55% -0.55% 2.6M
|
Health Technology
|
| O: -3.25%
H: 5.48%
C: 4.71%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: 0.05%
H: 3.56%
C: 1.09%
covid vaccine research covid-19
Thanks to Accelerated COVID-19 Research, New Therapeutic Vaccines May Soon Be Upon Us
Published: 2021-03-12 (Crawled : 14:21) - prnewswire.com
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.8%
H: 1.16%
C: 0.77%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.63%
H: 1.03%
C: 0.96%
MRNA S | $101.44 -0.55% -0.55% 2.6M
|
Health Technology
|
| O: -4.58%
H: 3.51%
C: 2.2%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: -3.18%
H: 3.97%
C: 3.97%
covid vaccine research covid-19
U.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older
Published: 2021-01-12 (Crawled : 15:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.14%
H: 0.02%
C: -2.38%
fda vaccine license fda acceptance order pneumococcal
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.